PCM
BEAM icon

Pathway Capital Management’s Beam Therapeutics BEAM Stock Holding History

Pathway Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-112,197
Closed -$14.4M – 20
2021
Q2 		$14.4M Buy
112,197
+74,798
+200% +$5.96M 5.74% 8
2021
Q1 		$2.99M Buy
+37,399
New +$3.56M 16.59% 3

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pathway Capital Management's BEAM Position: Q3 2021 in Review

Pathway Capital Management sold out of Beam Therapeutics (BEAM) in Q3 2021, closing a stake of 112,197 shares — an estimated $14.4M sold.

Pathway Capital Management first reported a position in BEAM in Q1 2021 and held it in 2 quarters. The position peaked at $14.4M in Q2 2021. 231 funds tracked by Wall St. Rank hold BEAM as of Q3 2021.

  • Pathway Capital Management reported no remaining Beam Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Pathway Capital Management sold 112,197 Beam Therapeutics shares in Q3 2021, an estimated $14.4M.
  • Pathway Capital Management first reported a position in Beam Therapeutics in Q1 2021 and held it in 2 quarters.
  • Pathway Capital Management's Beam Therapeutics position peaked at $14.4M in Q2 2021.
  • 231 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2021.

Based on Pathway Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.